Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia

Taher A. T., Porter J. B., Viprakasit V., Kattamis A., Chuncharunee S., Sutcharitchan P., ...More

BRITISH JOURNAL OF HAEMATOLOGY, vol.168, no.2, pp.284-290, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 168 Issue: 2
  • Publication Date: 2015
  • Doi Number: 10.1111/bjh.13119
  • Journal Name: BRITISH JOURNAL OF HAEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.284-290
  • Keywords: iron overload, chelation therapy, non-transfusion-dependent thalassaemia, liver iron concentration, serum ferritin, BETA-THALASSEMIA, MAGNETIC-RESONANCE, INTERMEDIA, OVERLOAD, MORBIDITY
  • Istanbul University Affiliated: Yes

Abstract

Liver iron concentration (LIC) assessment by magnetic resonance imaging (MRI) remains the gold standard to diagnose iron overload and guide iron chelation therapy in patients with non-transfusion-dependent thalassaemia (NTDT). However, limited access to MRI technology and expertise worldwide makes it practical to also use serum ferritin assessments. The THALASSA (assessment of Exjade((R)) in non-transfusion-dependent THALASSemiA patients) study assessed the efficacy and safety of deferasirox in iron-overloaded NTDT patients and provided a large data set to allow exploration of the relationship between LIC and serum ferritin. Using data from screened patients and those treated with deferasirox for up to 2years, we identified clinically relevant serum ferritin thresholds (for when MRI is unavailable) for the initiation of chelation therapy (>800g/l), as well as thresholds to guide chelator dose interruption (<300g/l) and dose escalation (>2000g/l). (clinicaltrials.gov identifier: NCT00873041).